- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Experimental Diabetes Research
Volume 2010 (2010), Article ID 176361, 11 pages
The Role of Rho Kinase in Sex-Dependent Vascular Dysfunction in Type 1 Diabetes
1The Department of Veterans Affairs Iowa City Health Care System, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, IA 52246, USA
2Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, IA 52242, USA
3Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, IA 52242, USA
Received 17 September 2009; Revised 1 December 2009; Accepted 14 January 2010
Academic Editor: Subrata K. Chakrabarti
Copyright © 2010 Daniel W. Nuno and Kathryn G. Lamping. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. M. Newton, A. Z. LaCroix, S. R. Heckbert, L. Abraham, D. McCulloch, and W. Barlow, “Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes,” Diabetes Care, vol. 26, no. 10, pp. 2810–2816, 2003.
- V. Jayagopal, P. Albertazzi, E. S. Kilpatrick, et al., “Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes,” Diabetes Care, vol. 25, no. 10, pp. 1709–1714, 2002.
- S. J. Lee, D. W. Lee, K. S. Kim, and I. K. Lee, “Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes,” Diabetes Research and Clinical Practice, vol. 54, supplement 2, pp. S81–S92, 2001.
- M. C. Monti, J. T. Lonsdale, C. Montomoli, R. Montross, E. Schlag, and D. A. Greenberg, “Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4650–4655, 2007.
- K. Raile, A. Galler, S. Hofer, et al., “Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex,” Diabetes Care, vol. 30, no. 10, pp. 2523–2528, 2007.
- D. Dabelea, G. Kinney, J. K. Snell-Bergeon, et al., “Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study,” Diabetes, vol. 52, no. 11, pp. 2833–2839, 2003.
- J. E. Roeters van Lennep, H. T. Westerveld, D. W. Erkelens, and E. E. van der Wall, “Risk factors for coronary heart disease: implications of gender,” Cardiovascular Research, vol. 53, no. 3, pp. 538–549, 2002.
- W. B. Kannel and P. W. F. Wilson, “Risk factors that attenuate the female coronary disease advantage,” Archives of Internal Medicine, vol. 155, no. 1, pp. 57–61, 1995.
- W. B. Kannel and D. L. McGee, “Diabetes and cardiovascular disease. The Framingham study,” Journal of the American Medical Association, vol. 241, no. 19, pp. 2035–2038, 1979.
- E. Barrett-Connor and D. L. Wingard, “Sex differential in ischemic heart disase mortality in diabetics: a prospective population-based study,” American Journal of Epidemiology, vol. 118, no. 4, pp. 489–496, 1983.
- W. G. Mayhan, H. Sun, and S. D. Irvine, “Influence of gender on dilatation of the basilar artery during diabetes mellitus,” Brain Research, vol. 930, no. 1-2, pp. 182–190, 2002.
- R. A. Brown, M. F. Walsh, and J. Ren, “Influence of gender and diabetes on vascular and myocardial contractile function,” Endocrine Research, vol. 27, no. 4, pp. 399–408, 2001.
- A. A. Ajayi, H. Hercule, J. Cory, B. E. Hayes, and A. O. Oyekan, “Gender difference in vascular and platelet reactivity to thromboxane -mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats,” Diabetes Research and Clinical Practice, vol. 59, no. 1, pp. 11–24, 2003.
- A. L. García-Villalón, E. Sanz, L. Monge, et al., “Vascular reactivity to vasopressin during diabetes: gender and regional differences,” European Journal of Pharmacology, vol. 459, no. 2-3, pp. 247–254, 2003.
- D. W. Nuno, V. P. Korovkina, S. K. England, and K. G. Lamping, “RhoA activation contributes to sex differences in vascular contractions,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 9, pp. 1934–1940, 2007.
- S. Chrissobolis, K. Budzyn, P. D. Marley, and C. G. Sobey, “Evidence that estrogen suppresses Rho-kinase function in the cerebral circulation in vivo,” Stroke, vol. 35, no. 9, pp. 2200–2205, 2004.
- K. G. Lamping and F. M. Faraci, “Role of sex differences and effects of endothelial NO synthase deficiency in responses of carotid arteries to serotonin,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 4, pp. 523–528, 2001.
- F. M. Faraci, K. G. Lamping, M. L. Modrick, M. J. Ryan, C. D. Sigmund, and S. P. Didion, “Cerebral vascular effects of angiotensin II: new insights from genetic models,” Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 4, pp. 449–455, 2006.
- H. Shimokawa and M. Rashid, “Development of Rho-kinase inhibitors for cardiovascular medicine,” Trends in Pharmacological Sciences, vol. 28, no. 6, pp. 296–302, 2007.
- D. W. Nuno, J. S. Harrod, and K. G. Lamping, “Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice,” American Journal of Physiology, vol. 297, no. 4, pp. H1469–H1477, 2009.
- M. Tamura, H. Nakao, H. Yoshizaki, et al., “Development of specific Rho-kinase inhibitors and their clinical application,” Biochimica et Biophysica Acta, vol. 1754, no. 1-2, pp. 245–252, 2005.
- T. Ishizaki, M. Uehata, I. Tamechika, et al., “Pharmacological properties of Y-27632, a specific inhibitor of Rho- associated kinases,” Molecular Pharmacology, vol. 57, no. 5, pp. 976–983, 2000.
- M. Uehata, T. Ishizaki, H. Satoh, et al., “Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension,” Nature, vol. 389, no. 6654, pp. 990–994, 1997.
- M. Ikenoya, H. Hidaka, T. Hosoya, M. Suzuki, N. Yamamoto, and Y. Sasaki, “Inhibition of Rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor,” Journal of Neurochemistry, vol. 81, no. 1, pp. 9–16, 2002.
- Y. Sasaki, M. Suzuki, and H. Hidaka, “The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway,” Pharmacology and Therapeutics, vol. 93, no. 2-3, pp. 225–232, 2002.
- C. Breitenlechner, M. Gaßel, H. Hidaka, et al., “Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity,” Structure, vol. 11, no. 12, pp. 1595–1607, 2003.
- R. M. Vicari, B. Chaitman, D. Keefe, et al., “Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1803–1811, 2005.
- T. Hattori, H. Shimokawa, M. Higashi, et al., “Long-term inhibition of rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice,” Circulation, vol. 109, no. 18, pp. 2234–2239, 2004.
- K. Abe, S. Tawara, K. Oi, et al., “Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice,” Journal of Cardiovascular Pharmacology, vol. 48, no. 6, pp. 280–285, 2006.
- R. Arita, Y. Hata, S. Nakao, et al., “Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage,” Diabetes, vol. 58, no. 1, pp. 215–226, 2009.
- O. A. Sandu, L. Ragolia, and N. Begum, “Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation,” Diabetes, vol. 49, no. 12, pp. 2178–2189, 2000.
- K. Kauser and G. M. Rubanyi, “Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae,” American Journal of Physiology, vol. 267, no. 6, pp. H2311–H2317, 1994.
- J. Hiroki, H. Shimokawa, Y. Mukai, T. Ichiki, and A. Takeshita, “Divergent effects of estrogen and nicotine on Rho-kinase expression in human coronary vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 326, no. 1, pp. 154–159, 2004.
- N. Morikage, H. Kishi, M. Sato, et al., “Cholesterol primes vascular smooth muscle to induce sensitization mediated by a sphingosylphosphorylcholine-Rho-kinase pathway: possible role for membrane raft,” Circulation Research, vol. 99, no. 3, pp. 299–306, 2006.
- P. Deedwania, M. Kosiborod, E. Barrett, et al., “Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism,” Circulation, vol. 117, no. 12, pp. 1610–1619, 2008.
- Y. Böttcher, D. Schleinitz, A. Tönjes, M. Blüher, M. Stumvoll, and P. Kovacs, “R1467H variant in the rho guanine nucleotide exchange factor 11 (ARHGEF11) is associated with impaired glucose tolerance and type 2 diabetes in German Caucasians,” Journal of Human Genetics, vol. 53, no. 4, pp. 365–367, 2008.
- M. Fu, M. M. Sabra, C. Damcott, et al., “Evidence that Rho guanine nucleotide exchange factor 11 (ARHGEF11) on 1q21 is a type 2 diabetes susceptibility gene in the Old Order Amish,” Diabetes, vol. 56, no. 5, pp. 1363–1368, 2007.
- Y. Kikuchi, M. Yamada, T. Imakiire, et al., “A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats,” Journal of Endocrinology, vol. 192, no. 3, pp. 595–603, 2007.
- R. Sordella, M. Classon, K.-Q. Hu, et al., “Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development,” Developmental Cell, vol. 2, no. 5, pp. 553–565, 2002.
- R. Sordella, W. Jiang, G.-C. Chen, M. Curto, and J. Settleman, “Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis,” Cell, vol. 113, no. 2, pp. 147–158, 2003.
- H. Shimokawa, K. Hiramori, H. Iinuma, et al., “Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study,” Journal of Cardiovascular Pharmacology, vol. 40, no. 5, pp. 751–761, 2002.
- M. Shibuya, Y. Suzuki, K. Sugita, et al., “Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial,” Journal of Neurosurgery, vol. 76, no. 4, pp. 571–577, 1992.